远大医药(00512.HK)签订两份股份购买协议并获Telix药品大中华独家授权
远大医药(00512.HK)公布,与Telix集团达成合作,双方签订股份认购协议,公司将以2,500万美元认购Telix约7.6%股本权益,并与Telix签订独家授权、合作开发及商业化协议,累计将支付预付款及里程碑款项最多2.25亿美元,以获得Telix开发之已完成II期临床试验的前列腺癌药物「TLX591」、即将开展两个联用免疫药物的II期临床试验的用於治疗透明细胞肾细胞癌药物「TLX250」,及已获得FDA孤儿药认定及处於I/II期临床阶段的用於治疗胶质母细胞瘤药物「TLX101」等多款放射性核素偶联药物於大中华地区之独家开发、生产及商业化权益。
另外公司并与Telix签订独家商业合作协议,将获得Telix开发之已向FDA提交新药申请的用於前列腺癌影像诊断之「TLX591-CDx」、已获得FDA突破性疗法认定并处於III期临床阶段的用於透明细胞肾细胞癌的影像诊断「TLX250-CDx」,及用於前列腺癌影像诊断的「TLX599-CDx」在内的多款放射性核素偶联药物在大中华地区的生产及商业化权益。
另外公司与江苏省原子医学研究所签订战略合作备忘录,就放射性核素偶药物领域的药物研发、生产、检测及标准制定、临床前研究以及知识产权等领域合作内容达成一致意向,建立良好的合作机制并开展长期合作,逐步提高公司放射性核素偶联药物的开发、临床前研究及产品转化等能力。
公司亦与普尔伟业签署股份购买协议,将以最多1,000万元人民币代价收购普尔伟业全数股权。完成收购後,普尔伟业将成公司附属,公司亦将获得《放射性药品生产许可证》及《放射性药品经营许可证》,并获得在中国开展68Ga、177Lu、89Zr、90Y等多种放射性核素偶联药物的开发、生产及经营的相关资质。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.